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Abstract 
Cardiovascular Disease (CVD) is the most common cause of death in industrialized countries, and 
myocardial infarction (MI) is a major CVD with significant morbidity and mortality. Following MI, the 
left ventricle (LV) undergoes a wound healing response to ischemia that results in extracellular 
matrix (ECM) scar formation to replace necrotic myocytes. While ECM accumulation following MI is 
termed cardiac fibrosis, this is a generic term that does not differentiate between ECM 
accumulation that occurs in the infarct region to form a scar that is structurally necessary to 
preserve left ventricle (LV) wall integrity and ECM accumulation that increases LV wall stiffness to 
exacerbate dilation and stimulate the progression to heart failure. This review focuses on post-MI 
LV ECM remodeling, targeting the discussion on ECM biomarkers that could be useful for 
predicting MI outcomes.  
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Introduction 
Cardiovascular disease (CVD) is the most common cause of death in industrialized countries [1], 
and myocardial infarction (MI) contributes significantly to CVD mortality [2]. The prevalence of CVD 
is estimated to increase by 10% over the next 20 years, and by 2030 cause 23.6 million deaths 
each year worldwide [3]. In addition, public health costs for MI are estimated to increase three-fold 
over the next 2 decades [4].  
 Following MI, the left ventricle (LV) undergoes a series of molecular, cellular, and extracellular 
matrix (ECM) changes that progress over time to alter LV geometry and impair LV physiology [5]. 
The ECM is a dynamic and complex structure, which serves to preserve LV physiology under 
homeostasis and regulate the development of the infarct scar in response to MI. The balance 
between ECM synthesis and degradation defines net ECM accumulation (synthesis minus 
degradation), with ECM degradation prominent in the early MI response and ECM synthesis 
prominent in the later post-MI period [6,7]. Evaluating ECM flux over the MI time continuum may 
provide early diagnostic or prognostic indicators of LV remodeling and allow clinicians to stratify 
patients based on risk or treatment strategy. Biomarkers are currently used for the timely diagnosis 
of MI; however, their use to date has shown limited use in heart failure due to lack of specificity and 
selectivity [8]. For example, while infarct size and the extent of post-MI LV dilation tracks with 
adverse remodeling and progression to heart failure, there is a lot of individual variation in 
response that may be due to differences in intensity of the inflammatory response[9]. The 
development of ECM remodeling biomarkers that detect structural changes during MI would 
provide information for the time period that occurs after MI and before heart failure development. 
This review will focus on ECM remodeling in the post-MI LV and concentrates the discussion on 
ECM changes that could serve as biomarkers to predict MI outcomes. 
Cell structural and physiological changes induced by MI 
MI is defined as the occurrence of cardiomyocyte cell death due to prolonged ischemia that most 
frequently occurs due to coronary artery occlusion. MI generates an intense wound repair process, 
which includes one type of  LV remodeling characterized by robust inflammation and scar 
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formation [10]. Disruption of the ECM network due to degradation by matrix metalloproteinases 
(MMPs) interrupts the structural integrity and induces physiological impairment characterized by 
reductions in both systolic (due to myocyte loss) and diastolic (due to ECM) function [11]. LV 
remodeling encapsulates effects in the infarct region, which are structurally important for limiting 
infarct expansion induced LV dilation, and effects in the remote region, which increase LV wall 
stiffness [6,12]. A better understanding of the molecular and cellular LV remodeling events is 
important for maximizing long-term MI survival by limiting progression to heart failure. Figure 1 
depicts the molecular and cellular time continuum of the different MI response phases: 
inflammation, wound healing, and collagen deposition. 
 The fate of the myocardium following MI depends on the balance of several competing events, 
including pro- vs. anti-inflammatory processes and ECM degradation vs. synthesis pathways. 
Excessive ECM accumulation can increase myocardial stiffness [13–17] and impair electrical 
activity [18]. Understanding which factors contribute to this balance will provide mechanistic insight 
into how the progression to heart failure is stimulated and identify new targets to examine.  
 Myocyte cell physiology is immediately impaired after the onset of ischemia, and by 30 minutes 
of ischemia, cardiomyocytes undergo irreversible cell death that stimulates an acute inflammatory 
response by upregulating the complement pathway [19–21]. Neutrophils and macrophages 
infiltrate into the infarct region and release inflammatory mediators, including matrix 
metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP), to stimulate ECM 
degradation and necrotic cell removal [22]. While  macrophage influx occurs first, neutrophil influx 
rapidly exceeds that of the macrophage and by post-MI day 1,, the neutrophil is the predominant 
leukocyte component in the infarct region [23]. Neutrophil numbers peak at day 1 post-MI and 
return to baseline by days 5-7 post-MI [24]. Macrophage numbers (Mac-3+ cells) peak at day 3 
post-MI and begin to decline after day 7 [25]. ECM is cleaved by proteases to release necrotic 
myocytes; and these ECM peptide fragments generated by proteolytic processing stimulate 
fibroblasts into an activated form (Figure 2). Cardiac fibroblasts are the major ECM producers in 
the LV, and cardiac fibroblast numbers and polarization begin to increase by day 3 post-MI [26]. 
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The collagen-rich reparative scar begins to form around day 5 post-MI to replace the extensive loss 
of cardiomyocytes in the infarcted area [27]. 
Cardiac relevant ECM proteins induced by MI  
 The myocardial ECM is comprised of hundreds of components that include collagens, 
fibronectin, glycoproteins, glycosaminoglycans (GAGs), proteoglycans, and MMPs/TIMPs (Table 
1). Some of these proteins can have matricellular properties, hence having a regulatory role rather 
than a structural one [7,28,29]. The cardiac ECM can be conceptually divided into proteins that 
reside in the interstitial matrix (e.g., collagen I, collagen III, and fibronectin) and proteins that reside 
in the basement membrane (collagen types IV, V, VII, X, and XIV and laminin) [30–32]. The 
basement membrane is the highly organized sheet-like ECM layer found on the surface of the cell 
sarcolemma and plays a key role in sarcomere formation via interactions with integrins [33]. 
Fibrillar collagens 
 Historically, the cardiac ECM has been reported to be mainly composed of collagen; in the 
mammalian heart, approximately 85% of fibrillar collagen is type I, whereas type III comprises 
about 11% of total collagen [30,31,34]. In addition to comprising the bulk of the interstitial matrix, 
collagens (such as collagen XIII) may also play important structural roles in intercalated discs that 
form between cardiac myocytes [35]. Collagens are secreted as procollagens into the extracellular 
space, with the carboxy- and end-terminal peptides being proteolytically cleaved to form a mature 
collagen fibril [36]. Mature collagen is rendered insoluble and resistant to degradation via cross-
linking by the enzymes lysyl oxidase [36]. Myocardial collagen content shows a biphasic nature 
following MI, with collagen degradation dominating early and synthesis dominating later as 
collagen is organized into scar tissue. Early post-MI, during the inflammatory phase, collagen is 
degraded by MMPs released by infiltrating neutrophils and monocytes, allowing these inflammatory 
cells to effectively phagocytose necrotic cells and creating a favorable environment for 
angiogenesis [37]. Proteolytically cleaved ECM fragments (matricryptins or matrikines) have 
important post-MI biological roles, including effects on cell proliferation, migration, differentiation, 
and inflammation [6].  Following the inflammatory phase, collagen deposition becomes favored 
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over degradation. In rats with MI, collagen III gene expression is induced 2 days post-MI and 
continues to increase by 21 days post-MI, whereas collagen I gene expression is increased 4 days 
post-MI, peaks at 7 days post-MI, and remains at that level by 21 days post-MI [38]. The increase 
in collagen content remains throughout the life of the infarct scar and plays a crucial role in the 
maintenance or deterioration of cardiac physiology and the progression to heart failure (HF).  
 Expression of collagen cross-linking enzymes is also elevated during the maturation phase to 
enhance overall LV stiffness. Lysyl oxidase is ~5-fold elevated at day 3 post-MI, remains elevated 
by day 7, and then decreases [39]. Mice lacking matrix metalloproteinase-9 (MMP-9) are protected 
from MI-induced LV dilation, in part due to increased lysyl oxidase expression and collagen cross-
linking [40]. In a rat model of cardiac volume overload-induced heart failure, inhibition of lysyl 
oxidase with beta-aminoproprionitrile also offers cardioprotection [41,42]. Advanced glycation end-
product (AGE) are another source of collagen cross-linking that have been associated with poorer 
outcome post-MI [43]. Unlike cross-links produced by LOX, AGEs are formed spontaneously.In 
mice, methylglyoxal-AGEs are produced in the post-MI LV, suggesting a role for accumulation of 
collagen and functional loss of the heart [43]. These results indicate that the effect of LV stiffness 
on dilation is U-shaped rather than linear, with too much or too little having detrimental effects.  
Basement Membrane Proteins 
 The basement membrane is a dense network of ECM proteins that surrounds cardiomyocytes, 
and includes laminins, collagen type IV, and a number of proteoglycans [44,45]. Laminin α1 is 
involved in basement membrane assembly and architecture, and plays an important role in cell 
migration through interactions with integrins α3β1 and α6β1 [46]. Fragmentation of the cardiac 
laminin network occurs after 1 hour of occlusion and continues for up to 7 days following 
reperfusion [47]. Studies have shown that basement membrane thickness is significantly increased 
around intramyocardial capillaries in patients with acute MI, which may contribute to impairment of 
oxygen diffusion and hypoxic stress [48].  Autoantibodies against collagen type IV are increased in 
post-MI patients, which may be causative or contributory to impaired basement membrane 
structural integrity and consequently endothelial cell dysfunction [49]. Laminin-derived peptides 
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stimulate wound healing by facilitating angiogenesis [50]. Peptides derived from the degradation of 
collagen IV and perlecan play critical roles in angiogenesis, vascular structural integrity, and cell-
cell interactions following myocardial ischemic injury [51].  
Elastin 
 Elastin provides elasticity to tissues such as blood vessels and skin, and its expression is 
relatively low in the adult heart [33]. Elastin expression decreases in the post-MI scar, leading to 
decreased elasticity and resiliency to recoil, and contributing to stiffening of the scar tissue [52–55]. 
Implantation of COS-7 cells overexpressing elastin into the infarcted myocardium 6 days post-MI 
partially attenuated the decreases in fractional shortening (58% decrease in control rats versus 
29% decrease in treated rats) and decreased infarct expansion by nearly 2-fold at 8-weeks post-
MI, suggesting that elastin may be a therapeutic target for improving infarct strength and elasticity 
[42]. Like collagen, elastin can be cross-linked by lysyl oxidase, altering its tensile strength [33]. 
Fibronectin 
 Fibronectin is a glycoprotein that provides a scaffold for the infiltration of connective tissue and 
inflammatory cells [56]. Fibronectin is expressed in the developing heart and is a minor component 
of the adult uninjured LV [57]. Fibronectin is induced in the adult heart in response to MI, produced 
mainly by fibroblasts and endothelial cells. The alternatively spliced extra domain A (EDA) of 
fibronectin acts as a pro-inflammatory agent [58]. Fibronectin increases more than 10-fold in the 
infarcted area at day 2 post-MI and is believed to contribute to an increase in mechanical strength 
of the infarcted wall. 
Proteoglycans 
 Proteoglycans are proteins covalently bound to long polysaccharide chains called 
glycosaminoglycans, including chondroitin/dermatan sulfate, keratin sulfate, and heparan sulfate 
[43,44]. Proteoglycans have been implicated in regulating the extent and organization of the 
collagen matrix [59]. Hyaluronan is a unique glycosaminoglycan in that it is not bound to a core 
protein, nor is it sulfated. Hyaluronan is increased post-MI in the LV infarct, and the generation of 
hyaluronan fragments promote inflammation, such that clearance of hyaluronan fragments is 
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necessary for resolution of post-MI inflammation [60,61]. Administration of IL-10, an anti-
inflammatory cytokine, may improve functional outcomes post-MI by downregulating 
hyaluronidase-3 and thuspreventing hyaluronan fragmentation and improving inflammation 
resolution [62].  
 Decorin binds and regulates assembly of collagen I and III fibrils and binds the pro-fibrotic 
transforming growth factor-beta (TGF-β) to inhibit its activity [48]. In vitro, collagen fibrils form more 
slowly and are of smaller diameter in the presence of decorin than those formed spontaneously, 
linking decorin with maintaining spatial order of collagen fibrils [63–65]. In rats, decorin increases 
by over 30% at week 5 post-MI and doubles by week 13 [63]. Mice lacking decorin show 
disorganized collagen fibril formation (lower packing density and increased heterogeneity in fibril 
size), more dilation (25% increase in LV circumference 2 weeks post-MI), and impaired physiology 
(ejection fraction reduced ~2-fold at 8 weeks post-MI) [66].  
 Versican, the major hyalectan (hyaluronan-binding proteoglycan) expressed in the LV,  
mediates inflammatory cell-cell and cell-matrix interactions in the infarcted heart and is primarily 
expressed by infiltrating monocytes [67]. Versican is induced 6 hours following MI and peaks at 2 
days, then declines gradually. Versican is also necessary for normal cardiac and vascular 
development [68]. 
Matricellular Proteins 
Matricellular proteins such as osteopontin, galectin-3, periostin, secreted protein acidic and rich in 
cysteine (SPARC), thrombospondin, and tenascins are secreted by myocardial resident and 
infiltrating cells and play non-structural roles in the cardiac ECM [69].  Matricellular proteins 
mediate processes such as cell adhesion, migration, growth, and differentiation.  
 Osteopontin is present at very low levels under basal conditions [70]. After MI, osteopontin 
expression markedly increases by 40-fold in the infarct region [70,71]. Osteopontin expression 
coincides with the development of pressure overload-induced heart failure, and may play a 
contributory role through its stimulatory effects on inducible nitric oxide synthase expression [71]. 
However, osteopontin may be cardioprotective post-MI, as osteopontin null mice show 1.6-fold 
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increased normalized LV volume without concomitant increases in infarct collagen content 14 days 
following MI, suggesting that osteopontin is essential for collagen deposition and healing post-MI 
[72]. Osteopontin is cleaved at multiple sites by MMPs, including MMP-9, which may decrease its 
cardioprotective actions [72].  
 Galectin-3, a lectin expressed by inflammatory cells, particularly macrophages, plays critical 
roles in stimulating both inflammation and fibrosis, mainly by activating TGF-β, IL-1, and IL-2 
signaling [44]. In mice, increased galectin-3 expression can be detected as early as 30 minutes 
post-MI, and is increased 3-fold by 24 hours [73]. At 7 days post-MI, mice lacking galectin-3 have 
more dilation (~10% increase in end-diastolic diameter), and decreased LV physiology (25% 
decreased ejection fraction and fractional shortening) [74].  
 Periostin, a collagen chaperone, is essentially undetectable in the adult myocardium except in 
valvular tissue, and is highly expressed in the infarct region 3 days post-MI mainly in cardiac 
fibroblasts [75]. Periostin appears to play dichotomous roles post-MI, being critical for normal 
healing and scar repair in the short term, but also contributing to cardiac fibrosis and LV stiffening 
in the long term. Mice lacking periostin have over 2-fold increased rupture rates 7 days post-MI and 
display 2-fold lower collagen content and 3-fold decreased cross-linked collagen [61]. In a porcine 
model, delivery of a periostin-derived peptide 2 days post-MI improves ejection fraction by about 
25% at 3 months, but also leads to increases in myocardial fibrosis (6-fold increases in collagen 
content) in the remote region at one and 12 weeks post-treatment, limiting its clinical application as 
a viable therapeutic strategy [76]. ECM peptides have been well-studied in wound healing 
therapeutics, and there are a number of reasons for using a peptide rather than a whole molecule 
[77,78]. Peptides are easier to deliver, and cleaved protein fragments often have different functions 
than the whole molecule. 
 SPARC is a matricellular protein expressed by cardiac fibroblasts and endothelial cells that 
serves as an essential chaperone for procollagen processing and assembly of collagen fibrils [81]. 
SPARC expression is increased ~2-fold at 3 days post-MI, and mice lacking SPARC show less LV 
dilation (25% lower end-diastolic volume) and 33% increased ejection fraction following MI [81]. 
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Cartilage oligomeric matrix protein (COMP) is a matricellular calcium-binding protein belonging to 
the thrombospondin family, which participates in cellular responses to growth factors and cytokines 
[79]. High levels of COMP have shown to be associated with lower risk of incident MI, suggesting a 
beneficial role in individuals without incident cardiovascular disease [80]. In this study, intact 
COMP was measured by a commercially available ELISA. As COMP is known to be degraded by 
ADAMTS7 [81] an assay measuring ADAMTS7-generated cleavage fragments of COMP may 
reveal a relationship between ADAMTS7 and COMP that has not yet been explored in the MI 
setting. 
MMP roles in MI 
 Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases responsible for ECM 
degradation and proteolytic activation of ECM proteins, inflammatory mediators, matricellular 
proteins, and other MMPs within the infarct region (Table 2) [82,83]Increased MMP activity in the 
vasculature can also lead to collagen degradation in fibro-atheromas, potentially resulting in plaque 
rupture and subsequent MI [82]. MMPs, therefore, are involved in all stages from atherosclerosis 
development to MI, post-MI wound healing, and progression to HF. MMP activity is dependent on 
the concentration of active enzyme and on the presence of a family of naturally occurring tissue 
inhibitors of metalloproteinases (TIMPs) [84]. Following MI, MMPs facilitate ECM degradation and 
recruit inflammatory cells to remove the necrotic cardiomyocytes. Initially the upregulation of pro-
inflammatory cytokines results in robust MMP activation. After long-term stimulation of pro-
inflammatory cytokines, TIMP level increase leading to decreased MMP/TIMP ratio and increases 
in fibrillar collagen deposition [85].  
 Of the 25 MMPs described to date, human MMP-1 has the highest affinity for fibrillar collagen 
and preferentially degrades collagen type I and collagen type III. Increases in MMP-1 synthesis 
have been reported in the infarcted myocardium in pigs and humans [86]. Inactivation of MMP-1 
synthesis in the infarcted myocardium results in collagen accumulation, which in turn leads to a stiff 
and non-compliant LV and gradual cardiac dysfunction [87]. The interaction between MMP-1 and 
TIMP-1 is of critical relevance in the maintenance of the post-MI integrity of the cardiac collagen 
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network. The MMP-1:TIMP-1 ratio has been inversely correlated with ejection fraction in patients 
with either systolic or diastolic heart failure [88]. Using an MMP to TIMP ratio is artificial, however, 
because there are more than one MMP and more than one TIMP present in the post-MI 
myocardium. 
 MMP-2 and -9 are the most widely studied MMPs, because they have historically been the 
easiest to measure using gel zymograms [89,90]. In a rat MI model, MMP-2 and -9 expression 
increases within 24 hours post-MI. At day 14, MMP-2 expression peaks and returns to baseline 
after 10 weeks, whereas MMP-9 expression continues to be elevated until 16 weeks post-MI 
[91,92]. There are species differences in MMP and TIMP expression, as MMP-9 is returning to 
baseline values by day 7 post-MI in the mouse. Excessive MMP activity post-MI leads to ECM 
degradation, which increases LV compliance and promotes cardiac rupture [55]. As such, MMP-2 
deletion improves survival rates after MI by limiting cardiac rupture [93]. Infiltrating macrophages 
are a major source of MMP-9 [94], and MMP-9 deletion attenuates LV dilation post-MI [95,96]. This 
is mainly due to MMP-9 regulation of inflammation through its proteolytic activity of both ECM and 
cytokine substrates. MMP-9 mediates the post-MI degradation of CD36 to decrease macrophage 
phagocytosis of apoptotic neutrophils; MMP-9 deletion increased phagocytosis and neutrophil 
apoptosis to improve post-MI LV dilation [97]. MMP-9 promotes a pro-inflammatory macrophage 
phenotype, as MMP-9 deletion increases pro-reparative M2 markers in macrophages following MI 
[94]. Although a number of in vitro MMP-9 substrates have been identified, including collagens 
(type I, IV, V, VII, X and XIV), fibronectin, elastin, IL-8, Cxcl4, and IL-1β, the mechanisms whereby 
MMP-9 modulates LV remodeling post-MI have not been completely elucidated [98,99].  
 MMP-3 is a stromelysin sub-type, along with MMP-10 and MMP-11, and is actively involved in 
pro-MMP proteolysis [100]. Unlike MMP- 9, the active form of MMP-3 is down-regulated by day 3 in 
the infarct region [101]. Elevated levels of MMP-3 associate with increased MI risk, most likely due 
to MMP-3 acting as an upstream regulatory step in the activation of many MMPs [102]. MMP-7 is 
responsible for degrading a number of ECM and matricellular proteins, as well as non-ECM 
proteins such as connexin-43, contributing to the development of MI-related arrhythmias [21]. 
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MMP-7 protein levels are up-regulated 3-fold in both remote and infarct regions at 7 days post-MI 
[103]. Similar to MMP-9, MMP-7 deletion has been shown to be protective post-MI albeit through 
different mechanisms [104].  
 MMP-8 and -13 are two of the major collagenases in the heart [105]. In rats, MMP-8 levels 
increase after 2 weeks and remain high until 16 weeks post-MI [91]. In cryoinfarcted mice, MMP-8 
levels are increased 3 days post-MI, but return to normal by 2 weeks, suggesting potentially 
different roles for this MMP in rats and mice [105]. MMP-13 shows an identical post-MI pattern of 
expression to MMP-8, thus mediating collagen degradation early post-MI [105]. In patients, 
elevated levels of plasma MMP-8 early post-MI is correlated with poor prognosis whereas higher 
levels more than 20 months after MI is associated with relative preservation of LV systolic function, 
indicating a biphasic profile [106]. MMP-12 (macrophage metalloelastase) increases 3-fold in the 
LV infarct region at day 1 post-MI and remains upregulated until day 7. MMP-12 inhibition 
exacerbates cardiac dysfunction by prolonging neutrophil mediated inflammation [61]. 
Contrastingly, MMP-28 decreases post-MI as the source moves from the highly abundant myocyte 
to macrophage. MMP-28 deletion aggravated MI-induced LV dysfunction and rupture as a result of 
defective inflammatory response and scar formation by suppressing M2 macrophage activation[5]. 
 TIMP-1 (29 kDa), a glycoprotein member of the TIMP family, co-localizes with MMP-1 in 
normal myocardium and is expressed by cardiac fibroblasts and myocytes [107–110]. TIMP-1 
expression increases early, peaks at day 1 and remains elevated through day 21 post-MI 
[91,111,112]. Circulating TIMP-1 levels closely associate with markers of HF severity, systemic 
inflammation, and LV remodeling [113]. In addition, high levels of TIMP-1 are associated with 
diastolic dysfunction [114]. TIMP-1 null mice have a greater degree of LV dilation post-MI 
[114,115]. TIMP-2 levels increase by 2 weeks post-MI, correlating with deposition of ECM by 
infiltrating myofibroblasts, and return to baseline after 8 weeks during the late remodeling phase 
[91]. In contrast, TIMP-3 and -4 are significantly reduced post-MI [91,112]. TIMP-3 has 
cardioprotective functions, as TIMP-3 deletion leads to spontaneous dilated cardiomyopathy, and 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
13 
 
delivery of recombinant TIMP-3 post-MI improves LV ejection fraction, decreases LV dilation, and 
attenuates infarct expansion [116]. 
Biomarkers of MI: current state of the field 
 The use of biomarkers for early diagnosis of acute MI has been extremely valuable over the 
past 40 years [117]. The most widely established diagnostic biomarker of MI is cardiac troponin 
(cTn). The available assays target the  C, I, or T subunits of troponin, which control the calcium 
mediated interaction of actin and myosin, leading to contraction and relaxation of the striated 
muscle [118]. Troponin I (cTnI) and troponin T (cTnT) are measured when they are released from 
cardiac myocytes upon myocardial damage. This biomarker is highly specific to cardiac tissue, 
since cTnI and cTnT have additional residues at the N- terminal end compared to the skeletal 
isoform of troponin [119]. Assays for troponins do present some disadvantages, including: high 
variability across commercial source; there could be misleading cTn levels in patients who receive 
reperfusion therapy; and there is no correlation between cTn and histopathology [10]. 
Nevertheless, cTn has since the year 2000 been the preferred biomarker for MI diagnosis [10].  
 C-reactive protein (CRP), myoglobin, and creatinine kinase (CK-MB) have been proposed as 
alternatives to cTn. CRP is a nonspecific acute-phase reactant protein produced in the liver used 
as marker of acute inflammation. Its use in MI is limited, since levels vary according to ethnicity, 
gender, genetics, and body weight. CRP is also non-specific for MI over other inflammatory 
conditions and has actually been described as a good indicator for non-cardiac pathologies 
[120,121]. CK-MB is an enzyme primarily located in the cardiac muscle. The MB isoenzyme is 
released upon myocardial injury [122]. During acute MI, the level of CK-MB doubles in the first 6 
hours, and peaks within 12-24 hours [123,124].  CK-MB is a good indicator of infarct size and 
predicts risk of re-infarction. This marker elevates later than cTn and has in several cases been 
shown to be less sensitive and specific than cTn. Myoglobin is a small protein localized in the 
cytoplasm of cardiac and skeletal muscle cells. Due to its small size, myoglobin is rapidly released 
into the circulation upon injury and is generally one of the earliest to appear in the circulation. 
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Elevated levels can be observed 0.2-2 hours after acute MI, which is considered rapid; due to its 
presence in skeletal muscle, however, this marker lacks tissue specificity [125,126]. 
General perspectives on ideal biomarker(s) of MI remodeling: opportunities for identifying 
targets 
 The ideal biomarker of MI response should be as non-invasive as possible and should monitor 
disease progression and predict long-term prognosis following MI. The biomarker assay should be 
easy to perform, reproducible, accurate, fast, and inexpensive. While cardiac-specificity is 
important to ensure no cross reactivity to other biological processes, it is not essential if MI is the 
only inflammatory pathology present [118,127]. Such non-invasive biomarkers may provide 
patients and their physicians with a better and timely assessment of diagnosis as well as 
surveillance of progression and response to treatment. The ECM proteome, which is strongly 
regulated during MI, may be a large source of potential new targets. 
Neo-epitope biomarkers of ECM peptides: an opportunity for post-MI monitoring 
 A finely regulated balance between CM degradation and synthesis is required for 
maintenance of tissue homeostasis. In pathological conditions, such as cardiac fibrosis, this 
balance is disrupted. An excessive production and accumulation of ECM proteins combined with 
dysregulated turnover contributes to post-MI cardiac remodeling and its progression to HF. The 
neo-epitope technology takes into consideration the action of proteases such as MMPs, which are 
active post-MI and work on ECM proteins at specific sites, to identify specific markers [128]. 
Immunoassays detecting neo-epitope peptides generated after protease cleavage and released 
into circulation would provide information on the dynamic turnover of the ECM and distinguish 
between responses that favor ECM degradation over formation (Figure 3). Targeting either 
protease-mediated fragmentation products (indicative of protein degradation) or the pro-peptide 
that is cleaved off the molecule during its maturation (indicative of protein formation) will provide 
information on ECM turnover. ECM degradation fragments not only reflect active connective tissue 
remodeling, the fragments can also acquire bioactive properties and be key mechanistic players in 
LV remodeling [78].  
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Both cardiac fibroblasts and cardiac myocytes are sources of IL-33 
. 
 
 Neo-epitope biomarkers have already proven useful as serological and urinary markers of ECM 
remodeling in several organ injury models, including liver, lung [129–133], and kidney [134–136] 
and could potentially be applied to myocardial fibrosis following MI. Elevated circulating carboxy-
terminal telopeptide of collagen type I (CITP), a biomarker of collagen degradation, is elevated 2 
days post-MI, peaks at 3 days, and remains at peak levels for 14 days [27]. Elevated CITP is 
associated with poor long-term clinical outcomes including mortality, cardiac arrest, heart failure, 
and recurrent MI for up to 1 year post-MI [27]. Other circulating peptides released during collagen 
synthesis, such as 
Poor outcome events such as death, 
development of HF, and recurrent MI significantly increase in patients presenting with elevated 
serum collagen matricryptins (matrikines) [27–31].  
 
Galectin-3 is up-regulated in animal 
models of HF and can be detected before the development of clinical HF [143–145].
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 The use of mass spectrometry based proteomics has gained increasing interest, due to its 
ability to determine changes in the ECM of the heart and other tissues [6,149]. Proteomics can be 
used to identify new biomarker targets in a variety of sample types and is used in biomarker 
assays [150,151]. Several excellent recent reviews have highlighted how proteomics has 
contributed to our understanding of ECM remodeling [28,152–157]. A major current limitation of 
ECM biomarkers for MI wound healing responses is that other organs may also contribute to the 
pool of neo-epitope peptides released in serum, since the same ECM proteins are present in more 
than one organ. Whether there is a signature biomarker panel that reflects MI response remains to 
be determined. 
Final considerations 
 The development of non-invasive ECM specific biomarkers could predict imbalanced tissue 
turnover, and thereby post-MI outcomes. Such biomarkers could facilitate clinical studies to both 
identify patients at risk of progressing to HF after MI and monitoring response to treatment 
strategies. 
Acknowledgements 
 We would like to thank past and present members of the Lindsey lab for their contributions to 
this knowledge. We acknowledge grant support from The Danish Research Foundation and the 
National Institute of Health HL075360, HL129823, HL051971, GM104357, GM114833, and 
GM115428, and from the Biomedical Laboratory Research and Development Service of the 
Veterans Affairs Office of Research and Development Award 5I01BX000505 and IK2BX003922. 
The content is solely the responsibility of the authors and does not necessarily represent the 
official views of the Danish Research Foundation, the National Institutes of Health, or the Veterans 
Administration.  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
17 
 
References 
[1] P. a. Heidenreich, J.G. Trogdon, O. a. Khavjou, J. Butler, K. Dracup, M.D. Ezekowitz, E.A. 
Finkelstein, Y. Hong, S.C. Johnston, A. Khera, D.M. Lloyd-Jones, S. a. Nelson, G. Nichol, D. 
Orenstein, P.W.F. Wilson, Y.J. Woo, Forecasting the future of cardiovascular disease in the 
United States: A policy statement from the American Heart Association, Circulation. 123 
(2011) 933–944. doi:10.1161/CIR.0b013e31820a55f5. 
[2] D. Mozaffarian, E.J. Benjamin, A.S. Go, D.K. Arnett, M.J. Blaha, M. Cushman, S. De 
Ferranti, J.P. Després, H.J. Fullerton, V.J. Howard, M.D. Huffman, S.E. Judd, B.M. Kissela, 
D.T. Lackland, J.H. Lichtman, L.D. Lisabeth, S. Liu, R.H. Mackey, D.B. Matchar, D.K. 
McGuire, E.R. Mohler, C.S. Moy, P. Muntner, M.E. Mussolino, K. Nasir, R.W. Neumar, G. 
Nichol, L. Palaniappan, D.K. Pandey, M.J. Reeves, C.J. Rodriguez, P.D. Sorlie, J. Stein, A. 
Towfighi, T.N. Turan, S.S. Virani, J.Z. Willey, D. Woo, R.W. Yeh, M.B. Turner, Heart disease 
and stroke statistics-2015 update : A report from the American Heart Association, 2015. 
doi:10.1161/CIR.0000000000000152. 
[3] C.D. Mathers, D. Loncar, Projections of global mortality and burden of disease from 2002 to 
2030., PLoS Med. 3 (2006) e442. doi:10.1371/journal.pmed.0030442. 
[4] P.A. Heidenreich, J.G. Trogdon, O.A. Khavjou, J. Butler, K. Dracup, M.D. Ezekowitz, E.A. 
Finkelstein, Y. Hong, S.C. Johnston, A. Khera, D.M. Lloyd-Jones, S.A. Nelson, G. Nichol, D. 
Orenstein, P.W.F. Wilson, Y.J. Woo, Forecasting the future of cardiovascular disease in the 
United States: A policy statement from the American Heart Association, Circulation. 123 
(2011) 933–944. doi:10.1161/CIR.0b013e31820a55f5. 
[5] Y. Ma, G. V Halade, J. Zhang, T.A. Ramirez, D. Levin, A. Voorhees, Y.-F. Jin, H.-C. Han, 
A.M. Manicone, M.L. Lindsey, Matrix metalloproteinase-28 deletion exacerbates cardiac 
dysfunction and rupture after myocardial infarction in mice by inhibiting M2 macrophage 
activation., Circ. Res. 112 (2013) 675–88. doi:10.1161/CIRCRESAHA.111.300502. 
[6] F.G. Spinale, N.G. Frangogiannis, B. Hinz, J.W. Holmes, Z. Kassiri, M.L. Lindsey, Crossing 
into the Next Frontier of Cardiac Extracellular Matrix Research, Circ. Res. 119 (2016) 1040–
1045. doi:10.1161/CIRCRESAHA.116.309916. 
[7] M.L. Lindsey, R.P. Iyer, R. Zamilpa, A. Yabluchanskiy, K.Y. DeLeon-Pennell, M.E. Hall, A. 
Kaplan, F.A. Zouein, D. Bratton, E.R. Flynn, P.L. Cannon, Y. Tian, Y.F. Jin, R.A. Lange, D. 
Tokmina-Roszyk, G.B. Fields, L.E. De Castro Brás, A Novel Collagen Matricryptin Reduces 
Left Ventricular Dilation Post-Myocardial Infarction by Promoting Scar Formation and 
Angiogenesis, J. Am. Coll. Cardiol. 66 (2015) 1364–1374. doi:10.1016/j.jacc.2015.07.035. 
[8] N. Iqbal, B. Wentworth, R. Choudhary, A.D.L.P. Landa, B. Kipper, A. Fard, A.S. Maisel, 
Cardiac biomarkers: new tools for heart failure management., Cardiovasc. Diagn. Ther. 2 
(2012) 147–64. doi:10.3978/j.issn.2223-3652.2012.06.03. 
[9] P.C. Westman, M.J. Lipinski, D. Luger, R. Waksman, R.O. Bonow, E. Wu, S.E. Epstein, 
Inflammation as a Driver of Adverse Left Ventricular Remodeling After Acute Myocardial 
Infarction., J. Am. Coll. Cardiol. 67 (2016) 2050–60. doi:10.1016/j.jacc.2016.01.073. 
[10] T. Joint, E. Society, A. College, Myocardial infarction redefined — A consensus document of 
The Joint European Society of Cardiology / American College of Cardiology Committee for 
the Redefinition of Myocardial Infarction The Joint European Society of Cardiology / 
American College of Card, 4636 (2000) 1502–1513. doi:10.1053/euhj.2000.2305. 
[11] S.W.M. van den Borne, J. Diez, W.M. Blankesteijn, J. Verjans, L. Hofstra, J. Narula, 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
18 
 
Myocardial remodeling after infarction: the role of myofibroblasts., Nat. Rev. Cardiol. 7 
(2010) 30–7. doi:10.1038/nrcardio.2009.199. 
[12] J. Díez, R. Querejeta, B. López, A. González, M. Larman, J.L. Martínez Ubago, Losartan-
dependent regression of myocardial fibrosis is associated with reduction of left ventricular 
chamber stiffness in hypertensive patients., Circulation. 105 (2002) 2512–7. 
http://www.ncbi.nlm.nih.gov/pubmed/12034658. 
[13] J.M. McLenachan, H.J. Dargie, Ventricular arrhythmias in hypertensive left ventricular 
hypertrophy. Relationship to coronary artery disease, left ventricular dysfunction, and 
myocardial fibrosis., Am. J. Hypertens. 3 (1990) 735–40. 
http://www.ncbi.nlm.nih.gov/pubmed/2145865. 
[14] J. Díez, Mechanisms of cardiac fibrosis in hypertension., J. Clin. Hypertens. (Greenwich). 9 
(2007) 546–50. http://www.ncbi.nlm.nih.gov/pubmed/17617765. 
[15] D. Fan, A. Takawale, J. Lee, Z. Kassiri, Cardiac fibroblasts, fibrosis and extracellular matrix 
remodeling in heart disease., Fibrogenesis Tissue Repair. 5 (2012) 15. doi:10.1186/1755-
1536-5-15. 
[16] Fan D et al., Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart 
disease, Fibrogenesis Tissue Repair. 5 (2012) 1–13. doi:10.1186/1755-1536-5-15. 
[17] N. Mewton, C.Y. Liu, P. Croisille, D. Bluemke, J.A.C. Lima, Assessment of myocardial 
fibrosis with cardiovascular magnetic resonance., J. Am. Coll. Cardiol. 57 (2011) 891–903. 
doi:10.1016/j.jacc.2010.11.013. 
[18] J.S. Janicki, G.L. Brower, The role of myocardial fibrillar collagen in ventricular remodeling 
and function., J. Card. Fail. 8 (2002) S319-25. doi:10.1054/jcaf.2002.129260. 
[19] N.G. Frangogiannis, The extracellular matrix in myocardial injury, repair, and remodeling., J. 
Clin. Invest. 127 (2017) 1600–1612. doi:10.1172/JCI87491. 
[20] K.Y. DeLeon-Pennell, C.A. Meschiari, M. Jung, M.L. Lindsey, Matrix Metalloproteinases in 
Myocardial Infarction and Heart Failure., Prog. Mol. Biol. Transl. Sci. 147 (2017) 75–100. 
doi:10.1016/bs.pmbts.2017.02.001. 
[21] S.D. Francis Stuart, N.M. De Jesus, M.L. Lindsey, C.M. Ripplinger, The crossroads of 
inflammation, fibrosis, and arrhythmia following myocardial infarction., J. Mol. Cell. Cardiol. 
91 (2016) 114–22. doi:10.1016/j.yjmcc.2015.12.024. 
[22] Y. Ma, L.E. De Castro Br??s, H. Toba, R.P. Iyer, M.E. Hall, M.D. Winniford, R.A. Lange, 
S.C. Tyagi, M.L. Lindsey, Myofibroblasts and the extracellular matrix network in post-
myocardial infarction cardiac remodeling, Pflugers Arch. Eur. J. Physiol. 466 (2014) 1113–
1127. doi:10.1007/s00424-014-1463-9. 
[23] V. Frodermann, M. Nahrendorf, Neutrophil–macrophage cross-talk in acute myocardial 
infarction, Eur. Heart J. 38 (2016) ehw085. doi:10.1093/eurheartj/ehw085. 
[24] A. Yabluchanskiy, Y. Ma, R.P. Iyer, M.E. Hall, M.L. Lindsey, Matrix metalloproteinase-9: 
Many shades of function in cardiovascular disease., Physiology (Bethesda). 28 (2013) 391–
403. doi:10.1152/physiol.00029.2013. 
[25] M.L. Lindsey, Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after 
myocardial infarction, AJP Hear. Circ. Physiol. 290 (2005) H232–H239. 
doi:10.1152/ajpheart.00457.2005. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
19 
 
[26] Y. Ma, R.P. Iyer, M. Jung, M.P. Czubryt, M.L. Lindsey, Cardiac Fibroblast Activation Post-
Myocardial Infarction: Current Knowledge Gaps, Trends Pharmacol. Sci. 38 (2017) 448–
458. doi:10.1016/j.tips.2017.03.001. 
[27] Y. Ma, G. V. Halade, M.L. Lindsey, Extracellular matrix and fibroblast communication 
following myocardial infarction, J. Cardiovasc. Transl. Res. 5 (2012) 848–857. 
doi:10.1161/CIRCULATIONAHA.111.087940.The. 
[28] J. Barallobre-Barreiro, M. Lynch, X. Yin, M. Mayr, Systems biology-opportunities and 
challenges: the application of proteomics to study the cardiovascular extracellular matrix., 
Cardiovasc. Res. 112 (2016) 626–636. doi:10.1093/cvr/cvw206. 
[29] E.C. Goldsmith, A.D. Bradshaw, M.R. Zile, F.G. Spinale, Myocardial fibroblast-matrix 
interactions and potential therapeutic targets., J. Mol. Cell. Cardiol. 70 (2014) 92–9. 
doi:10.1016/j.yjmcc.2014.01.008. 
[30] F.T. Bosman, I. Stamenkovic, Functional structure and composition of the extracellular 
matrix., J. Pathol. 200 (2003) 423–8. doi:10.1002/path.1437. 
[31] R.D. Brown, S.K. Ambler, M.D. Mitchell, C.S. Long, The cardiac fibroblast: therapeutic target 
in myocardial remodeling and failure., Annu. Rev. Pharmacol. Toxicol. 45 (2005) 657–87. 
doi:10.1146/annurev.pharmtox.45.120403.095802. 
[32] M. Paulssons, K. Saladin, Mouse heart laminin. Purification of the native protein and 
structural comparison with Engelbreth-Holm-Swarm tumor laminin, J. Biol. Chem. 264 
(1989) 18726–18732. 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&lis
t_uids=2478549. 
[33] H. Yang, T.K. Borg, H. Liu, B.Z. Gao, Interactive relationship between basement-membrane 
development and sarcomerogenesis in single cardiomyocytes., Exp. Cell Res. 330 (2015) 
222–32. doi:10.1016/j.yexcr.2014.08.020. 
[34] H.-B. Kwak, Aging, exercise, and extracellular matrix in the heart., J. Exerc. Rehabil. 9 
(2013) 338–47. doi:10.12965/jer.130049. 
[35] P. Hägg, T. Väisänen, A. Tuomisto, M. Rehn, H. Tu, P. Huhtala, S. Eskelinen, T. 
Pihlajaniemi, Type XIII collagen: a novel cell adhesion component present in a range of cell-
matrix adhesions and in the intercalated discs between cardiac muscle cells., Matrix Biol. 19 
(2001) 727–42. http://www.ncbi.nlm.nih.gov/pubmed/11223332. 
[36] M.R. Zile, C.F. Baicu, Biomarkers of diastolic dysfunction and myocardial fibrosis: 
application to heart failure with a preserved ejection fraction., J. Cardiovasc. Transl. Res. 6 
(2013) 501–15. doi:10.1007/s12265-013-9472-1. 
[37] C. Jourdan-LeSaux, J. Zhang, M.L. Lindsey, Extracellular matrix roles during cardiac repair, 
Life Sci. 87 (2010) 391–400. doi:10.1016/j.lfs.2010.07.010. 
[38] J.P. Cleutjens, M.J. Verluyten, J.F. Smiths, M.J. Daemen, Collagen remodeling after 
myocardial infarction in the rat heart., Am. J. Pathol. 147 (1995) 325–38. 
http://www.ncbi.nlm.nih.gov/pubmed/7639329. 
[39] J. González-Santamaría, M. Villalba, O. Busnadiego, M.M. López-Olañeta, P. Sandoval, J. 
Snabel, M. López-Cabrera, J.T. Erler, R. Hanemaaijer, E. Lara-Pezzi, F. Rodríguez-
Pascual, Matrix cross-linking lysyl oxidases are induced in response to myocardial infarction 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
20 
 
and promote cardiac dysfunction., Cardiovasc. Res. 109 (2016) 67–78. 
doi:10.1093/cvr/cvv214. 
[40] A.P. Voorhees, K.Y. DeLeon-Pennell, Y. Ma, G. V Halade, A. Yabluchanskiy, R.P. Iyer, E. 
Flynn, C.A. Cates, M.L. Lindsey, H.-C. Han, Building a better infarct: Modulation of collagen 
cross-linking to increase infarct stiffness and reduce left ventricular dilation post-myocardial 
infarction., J. Mol. Cell. Cardiol. 85 (2015) 229–39. doi:10.1016/j.yjmcc.2015.06.006. 
[41] E.C. El Hajj, M.C. El Hajj, V.K. Ninh, J.M. Bradley, M.A. Claudino, J.D. Gardner, Detrimental 
role of lysyl oxidase in cardiac remodeling., J. Mol. Cell. Cardiol. 109 (2017) 17–26. 
doi:10.1016/j.yjmcc.2017.06.013. 
[42] E.C. El Hajj, M.C. El Hajj, V.K. Ninh, J.D. Gardner, Cardioprotective effects of lysyl oxidase 
inhibition against volume overload-induced extracellular matrix remodeling., Exp. Biol. Med. 
(Maywood). 241 (2016) 539–49. doi:10.1177/1535370215616511. 
[43] N.J.R. Blackburn, B. Vulesevic, B. McNeill, C.E. Cimenci, A. Ahmadi, M. Gonzalez-Gomez, 
A. Ostojic, Z. Zhong, M. Brownlee, P.J. Beisswenger, R.W. Milne, E.J. Suuronen, 
Methylglyoxal-derived advanced glycation end products contribute to negative cardiac 
remodeling and dysfunction post-myocardial infarction., Basic Res. Cardiol. 112 (2017) 57. 
doi:10.1007/s00395-017-0646-x. 
[44] H. Yang, T.K. Borg, Z. Wang, Z. Ma, B.Z. Gao, Role of the basement membrane in 
regulation of cardiac electrical properties., Ann. Biomed. Eng. 42 (2014) 1148–57. 
doi:10.1007/s10439-014-0992-x. 
[45] A. Pozzi, P.D. Yurchenco, R. V Iozzo, The nature and biology of basement membranes., 
Matrix Biol. 57–58 (2017) 1–11. doi:10.1016/j.matbio.2016.12.009. 
[46] J. Tzu, M.P. Marinkovich, Bridging structure with function: structural, regulatory, and 
developmental role of laminins., Int. J. Biochem. Cell Biol. 40 (2008) 199–214. 
doi:10.1016/j.biocel.2007.07.015. 
[47] M. Dobaczewski, M. Bujak, P. Zymek, G. Ren, M.L. Entman, N.G. Frangogiannis, 
Extracellular matrix remodeling in canine and mouse myocardial infarcts., Cell Tissue Res. 
324 (2006) 475–88. doi:10.1007/s00441-005-0144-6. 
[48] M.P. V Begieneman, F.R.W. van de Goot, P.A.J. Krijnen, J. Fritz, W.J. Paulus, M.D. 
Spreeuwenberg, V.W.M. van Hinsbergh, H.W.M. Niessen, The basement membrane of 
intramyocardial capillaries is thickened in patients with acute myocardial infarction., J. Vasc. 
Res. 47 (2010) 54–60. doi:10.1159/000231721. 
[49] O. McLeod, P. Dunér, A. Samnegård, P. Tornvall, J. Nilsson, A. Hamsten, E. Bengtsson, 
Autoantibodies against basement membrane collagen type IV are associated with 
myocardial infarction, IJC Hear. Vasc. 6 (2015) 42–47. doi:10.1016/j.ijcha.2014.12.003. 
[50] K.M. Malinda, A.B. Wysocki, J.E. Koblinski, H.K. Kleinman, M.L. Ponce, Angiogenic laminin-
derived peptides stimulate wound healing., Int. J. Biochem. Cell Biol. 40 (2008) 2771–80. 
doi:10.1016/j.biocel.2008.05.025. 
[51] A. Lauten, A. Gerhard-Garcia, F. Suhr, J.H. Fischer, H.R. Figulla, W. Bloch, Impact of 
ischemia-reperfusion on extracellular matrix processing and structure of the basement 
membrane of the heart., PLoS One. 9 (2014) e92833. doi:10.1371/journal.pone.0092833. 
[52] C.M. Kielty, M.J. Sherratt, C.A. Shuttleworth, Elastic fibres., J. Cell Sci. 115 (2002) 2817–28. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
21 
 
http://www.ncbi.nlm.nih.gov/pubmed/12082143. 
[53] H. Yanagisawa, E.C. Davis, B.C. Starcher, T. Ouchi, M. Yanagisawa, J.A. Richardson, E.N. 
Olson, Fibulin-5 is an elastin-binding protein essential for elastic fibre development in vivo., 
Nature. 415 (2002) 168–71. doi:10.1038/415168a. 
[54] T. Nakamura, P.R. Lozano, Y. Ikeda, Y. Iwanaga, A. Hinek, S. Minamisawa, C.-F. Cheng, K. 
Kobuke, N. Dalton, Y. Takada, K. Tashiro, J. Ross Jr, T. Honjo, K.R. Chien, Fibulin-
5/DANCE is essential for elastogenesis in vivo., Nature. 415 (2002) 171–5. 
doi:10.1038/415171a. 
[55] T. Mizuno, D.A.G. Mickle, C.G. Kiani, R.-K. Li, Overexpression of elastin fragments in 
infarcted myocardium attenuates scar expansion and heart dysfunction., Am. J. Physiol. 
Heart Circ. Physiol. 288 (2005) H2819-27. doi:10.1152/ajpheart.00862.2004. 
[56] W. Casscells, H. Kimura, J.A. Sanchez, Z.X. Yu, V.J. Ferrans, Immunohistochemical study 
of fibronectin in experimental myocardial infarction., Am. J. Pathol. 137 (1990) 801–10. 
http://www.ncbi.nlm.nih.gov/pubmed/2221013. 
[57] M.H. Konstandin, H. Toko, G.M. Gastelum, P. Quijada, A. De La Torre, M. Quintana, B. 
Collins, S. Din, D. Avitabile, M. Völkers, N. Gude, R. Fässler, M.A. Sussman, Fibronectin is 
essential for reparative cardiac progenitor cell response after myocardial infarction., Circ. 
Res. 113 (2013) 115–25. doi:10.1161/CIRCRESAHA.113.301152. 
[58] F. Arslan, M.B. Smeets, P.W. Riem Vis, J.C. Karper, P.H. Quax, L.G. Bongartz, J.H. Peters, 
I.E. Hoefer, P.A. Doevendans, G. Pasterkamp, D.P. de Kleijn, Lack of fibronectin-EDA 
promotes survival and prevents adverse remodeling and heart function deterioration after 
myocardial infarction., Circ. Res. 108 (2011) 582–92. 
doi:10.1161/CIRCRESAHA.110.224428. 
[59] L. Schaefer, R.M. Schaefer, Proteoglycans: from structural compounds to signaling 
molecules., Cell Tissue Res. 339 (2010) 237–46. doi:10.1007/s00441-009-0821-y. 
[60] M. Rienks, A.-P. Papageorgiou, N.G. Frangogiannis, S. Heymans, Myocardial extracellular 
matrix: an ever-changing and diverse entity., Circ. Res. 114 (2014) 872–88. 
doi:10.1161/CIRCRESAHA.114.302533. 
[61] R.P. Iyer, N.L. Patterson, F.A. Zouein, Y. Ma, V. Dive, L.E. de Castro Brás, M.L. Lindsey, 
Early matrix metalloproteinase-12 inhibition worsens post-myocardial infarction cardiac 
dysfunction by delaying inflammation resolution., Int. J. Cardiol. 185 (2015) 198–208. 
doi:10.1016/j.ijcard.2015.03.054. 
[62] M. Jung, Y. Ma, R.P. Iyer, K.Y. DeLeon-Pennell, A. Yabluchanskiy, M.R. Garrett, M.L. 
Lindsey, IL-10 improves cardiac remodeling after myocardial infarction by stimulating M2 
macrophage polarization and fibroblast activation., Basic Res. Cardiol. 112 (2017) 33. 
doi:10.1007/s00395-017-0622-5. 
[63] S.D. Zimmerman, D.P. Thomas, S.G. Velleman, X. Li, T.R. Hansen, R.J. McCormick, Time 
course of collagen and decorin changes in rat cardiac and skeletal muscle post-MI., Am. J. 
Physiol. Heart Circ. Physiol. 281 (2001) H1816-22. 
http://www.ncbi.nlm.nih.gov/pubmed/11557576. 
[64] K.G. Vogel, J.A. Trotter, The effect of proteoglycans on the morphology of collagen fibrils 
formed in vitro., Coll. Relat. Res. 7 (1987) 105–14. 
http://www.ncbi.nlm.nih.gov/pubmed/3621881. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
22 
 
[65] K.G. Vogel, M. Paulsson, D. Heinegård, Specific inhibition of type I and type II collagen 
fibrillogenesis by the small proteoglycan of tendon., Biochem. J. 223 (1984) 587–97. 
http://www.ncbi.nlm.nih.gov/pubmed/6439184. 
[66] S.M. Weis, S.D. Zimmerman, M. Shah, J.W. Covell, J.H. Omens, J. Ross, N. Dalton, Y. 
Jones, C.C. Reed, R. V Iozzo, A.D. McCulloch, A role for decorin in the remodeling of 
myocardial infarction., Matrix Biol. 24 (2005) 313–24. doi:10.1016/j.matbio.2005.05.003. 
[67] K. Toeda, K. Nakamura, S. Hirohata, O.F. Hatipoglu, K. Demircan, H. Yamawaki, H. Ogawa, 
S. Kusachi, Y. Shiratori, Y. Ninomiya, Versican is induced in infiltrating monocytes in 
myocardial infarction., Mol. Cell. Biochem. 280 (2005) 47–56. doi:10.1007/s11010-005-
8051-4. 
[68] C.B. Kern, A. Wessels, J. McGarity, L.J. Dixon, E. Alston, W.S. Argraves, D. Geeting, C.M. 
Nelson, D.R. Menick, S.S. Apte, Reduced versican cleavage due to Adamts9 
haploinsufficiency is associated with cardiac and aortic anomalies., Matrix Biol. 29 (2010) 
304–16. doi:10.1016/j.matbio.2010.01.005. 
[69] M. Rienks, A.-P. Papageorgiou, N.G. Frangogiannis, S. Heymans, Myocardial extracellular 
matrix: an ever-changing and diverse entity., Circ. Res. 114 (2014) 872–88. 
doi:10.1161/CIRCRESAHA.114.302533. 
[70] N. a Trueblood, Z. Xie, C. Communal, F. Sam, S. Ngoy, L. Liaw,  a W. Jenkins, J. Wang, 
D.B. Sawyer, O.H. Bing, C.S. Apstein, W.S. Colucci, K. Singh, Exaggerated left ventricular 
dilation and reduced collagen deposition after myocardial infarction in mice lacking 
osteopontin., Circ. Res. 88 (2001) 1080–1087. doi:10.1161/hh1001.090842. 
[71] K. Singh, G. Sirokman, C. Communal, K.G. Robinson, C.H. Conrad, W.W. Brooks, O.H. 
Bing, W.S. Colucci, Myocardial osteopontin expression coincides with the development of 
heart failure., Hypertension. 33 (1999) 663–670. doi:10.1161/01.HYP.33.2.663. 
[72] M.L. Lindsey, F.A. Zouein, Y. Tian, R.P. Iyer, L.E. De Castro Brás, Osteopontin is 
proteolytically processed by matrix metalloproteinase 9 1 HHS Public Access, Can J Physiol 
Pharmacol. 93 (2015) 879–886. doi:10.1139/cjpp-2015-0019. 
[73] S. Hashmi, S. Al-Salam, Galectin-3 is expressed in the myocardium very early post-
myocardial infarction., Cardiovasc. Pathol. 24 (2015) 213–23. 
doi:10.1016/j.carpath.2014.12.001. 
[74] G.E. González, P. Cassaglia, S. Noli Truant, M.M. Fernández, L. Wilensky, V. Volberg, E.L. 
Malchiodi, C. Morales, R.J. Gelpi, Galectin-3 is essential for early wound healing and 
ventricular remodeling after myocardial infarction in mice., Int. J. Cardiol. 176 (2014) 1423–
5. doi:10.1016/j.ijcard.2014.08.011. 
[75] M. Shimazaki, K. Nakamura, I. Kii, T. Kashima, N. Amizuka, M. Li, M. Saito, K. Fukuda, T. 
Nishiyama, S. Kitajima, Y. Saga, M. Fukayama, M. Sata, A. Kudo, Periostin is essential for 
cardiac healing after acute myocardial infarction., J. Exp. Med. 205 (2008) 295–303. 
doi:10.1084/jem.20071297. 
[76] D. Ladage, E. Yaniz-Galende, K. Rapti, K. Ishikawa, L. Tilemann, S. Shapiro, Y. Takewa, J. 
Muller-Ehmsen, M. Schwarz, M.J. Garcia, J. Sanz, R.J. Hajjar, Y. Kawase, Stimulating 
myocardial regeneration with periostin Peptide in large mammals improves function post-
myocardial infarction but increases myocardial fibrosis., PLoS One. 8 (2013) e59656. 
doi:10.1371/journal.pone.0059656. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
23 
 
[77] C. Bonnans, J. Chou, Z. Werb, Remodelling the extracellular matrix in development and 
disease, Nat. Rev. Mol. Cell Biol. 15 (2014) 786–801. doi:10.1038/nrm3904. 
[78] F. Genovese, M.A. Karsdal, Protein degradation fragments as diagnostic and prognostic 
biomarkers of connective tissue diseases: understanding the extracellular matrix message 
and implication for current and future serological biomarkers, Expert Rev. Proteomics. 13 
(2016) 213–225. doi:10.1586/14789450.2016.1134327. 
[79] H. Chen, M.E. Herndon, J. Lawler, The cell biology of thrombospondin-1., Matrix Biol. 19 
(2000) 597–614. http://www.ncbi.nlm.nih.gov/pubmed/11102749. 
[80] T. Ueland, L.E. Laugsand, L.J. Vatten, I. Janszky, C. Platou, A.E. Michelsen, J.K. Damås, P. 
Aukrust, B.O. Åsvold, Extracellular matrix markers and risk of myocardial infarction: The 
HUNT Study in Norway, Eur. J. Prev. Cardiol. 24 (2017) 1161–1167. 
doi:10.1177/2047487317703826. 
[81] C.-J. Liu, W. Kong, K. Ilalov, S. Yu, K. Xu, L. Prazak, M. Fajardo, B. Sehgal, P.E. Di Cesare, 
ADAMTS-7: a metalloproteinase that directly binds to and degrades cartilage oligomeric 
matrix protein., FASEB J. 20 (2006) 988–90. doi:10.1096/fj.05-3877fje. 
[82] A.C. Newby, Metalloproteinases promote plaque rupture and myocardial infarction: A 
persuasive concept waiting for clinical translation., Matrix Biol. 44–46 (2015) 157–66. 
doi:10.1016/j.matbio.2015.01.015. 
[83] M.G. Rohani, W.C. Parks, Matrix remodeling by MMPs during wound repair., Matrix Biol. 
44–46 (2015) 113–21. doi:10.1016/j.matbio.2015.03.002. 
[84] R. Visse, H. Nagase, Matrix metalloproteinases and tissue inhibitors of metalloproteinases: 
structure, function, and biochemistry., Circ. Res. 92 (2003) 827–39. 
doi:10.1161/01.RES.0000070112.80711.3D. 
[85] D.L. Mann, Inflammatory mediators and the failing heart: past, present, and the foreseeable 
future., Circ. Res. 91 (2002) 988–98. http://www.ncbi.nlm.nih.gov/pubmed/12456484. 
[86] F.G. Spinale, M.L. Coker, B.R. Bond, J.L. Zellner, Myocardial matrix degradation and 
metalloproteinase activation in the failing heart: a potential therapeutic target., Cardiovasc. 
Res. 46 (2000) 225–38. http://www.ncbi.nlm.nih.gov/pubmed/10773226. 
[87] R.F. Foronjy, J. Sun, V. Lemaitre, J.M. D’Armiento, Transgenic expression of matrix 
metalloproteinase-1 inhibits myocardial fibrosis and prevents the transition to heart failure in 
a pressure overload mouse model., Hypertens. Res. 31 (2008) 725–35. 
doi:10.1291/hypres.31.725. 
[88] B. López, A. González, R. Querejeta, M. Larman, J. Díez, Alterations in the pattern of 
collagen deposition may contribute to the deterioration of systolic function in hypertensive 
patients with heart failure., J. Am. Coll. Cardiol. 48 (2006) 89–96. 
doi:10.1016/j.jacc.2006.01.077. 
[89] R.P. Iyer, N.L. Patterson, G.B. Fields, M.L. Lindsey, The history of matrix 
metalloproteinases: milestones, myths, and misperceptions, AJP Hear. Circ. Physiol. 303 
(2012) H919–H930. doi:10.1152/ajpheart.00577.2012. 
[90] R.P. Iyer, L.E. De Castro Brás, Y.F. Jin, M.L. Lindsey, Translating Koch’s postulates to 
identify matrix metalloproteinase roles in postmyocardial infarction remodeling: Cardiac 
metalloproteinase actions (carMA) postulates, Circ. Res. 114 (2014) 860–871. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
24 
 
doi:10.1161/CIRCRESAHA.114.301673. 
[91] J.T. Peterson, H. Li, L. Dillon, J.W. Bryant, Evolution of matrix metalloprotease and tissue 
inhibitor expression during heart failure progression in the infarcted rat., Cardiovasc. Res. 46 
(2000) 307–15. http://www.ncbi.nlm.nih.gov/pubmed/10773235. 
[92] A. Deten, H.C. Volz, A. Holzl, W. Briest, H.-G. Zimmer, Effect of propranolol on cardiac 
cytokine expression after myocardial infarction in rats., Mol. Cell. Biochem. 251 (2003) 127–
37. http://www.ncbi.nlm.nih.gov/pubmed/14575314. 
[93] S. Matsumura, S. Iwanaga, S. Mochizuki, H. Okamoto, S. Ogawa, Y. Okada, Targeted 
deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial 
infarction in mice., J. Clin. Invest. 115 (2005) 599–609. doi:10.1172/JCI22304. 
[94] A. Yabluchanskiy, Y. Ma, K.Y. DeLeon-Pennell, R. Altara, G. V Halade, A.P. Voorhees, N.T. 
Nguyen, Y.-F. Jin, M.D. Winniford, M.E. Hall, H.-C. Han, M.L. Lindsey, Myocardial Infarction 
Superimposed on Aging: MMP-9 Deletion Promotes M2 Macrophage Polarization., J. 
Gerontol. A. Biol. Sci. Med. Sci. 71 (2016) 475–83. doi:10.1093/gerona/glv034. 
[95] A. Ducharme, S. Frantz, M. Aikawa, E. Rabkin, M. Lindsey, L.E. Rohde, F.J. Schoen, R.A. 
Kelly, Z. Werb, P. Libby, R.T. Lee, Targeted deletion of matrix metalloproteinase-9 
attenuates left ventricular enlargement and collagen accumulation after experimental 
myocardial infarction., J. Clin. Invest. 106 (2000) 55–62. doi:10.1172/JCI8768. 
[96] S. Heymans, A. Luttun, D. Nuyens, G. Theilmeier, E. Creemers, L. Moons, G.D. Dyspersin, 
J.P. Cleutjens, M. Shipley, A. Angellilo, M. Levi, O. Nübe, A. Baker, E. Keshet, F. Lupu, J.M. 
Herbert, J.F. Smits, S.D. Shapiro, M. Baes, M. Borgers, D. Collen, M.J. Daemen, P. 
Carmeliet, Inhibition of plasminogen activators or matrix metalloproteinases prevents 
cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure., Nat. Med. 
5 (1999) 1135–42. doi:10.1038/13459. 
[97] K.Y. DeLeon-Pennell, Y. Tian, B. Zhang, C.A. Cates, R.P. Iyer, P. Cannon, P. Shah, P. 
Aiyetan, G. V Halade, Y. Ma, E. Flynn, Z. Zhang, Y.-F. Jin, H. Zhang, M.L. Lindsey, CD36 Is 
a Matrix Metalloproteinase-9 Substrate That Stimulates Neutrophil Apoptosis and Removal 
During Cardiac Remodeling., Circ. Cardiovasc. Genet. 9 (2016) 14–25. 
doi:10.1161/CIRCGENETICS.115.001249. 
[98] R. Zamilpa, E.F. Lopez, Y.A. Chiao, Q. Dai, G.P. Escobar, K. Hakala, S.T. Weintraub, M.L. 
Lindsey, Proteomic analysis identifies in vivo candidate matrix metalloproteinase-9 
substrates in the left ventricle post-myocardial infarction., Proteomics. 10 (2010) 2214–23. 
doi:10.1002/pmic.200900587. 
[99] O. Zitka, J. Kukacka, S. Krizkova, D. Huska, V. Adam, M. Masarik, R. Prusa, R. Kizek, 
Matrix metalloproteinases., Curr. Med. Chem. 17 (2010) 3751–68. 
http://www.ncbi.nlm.nih.gov/pubmed/20846107. 
[100] Q. Chen, M. Jin, F. Yang, J. Zhu, Q. Xiao, L. Zhang, Matrix metalloproteinases: 
Inflammatory regulators of cell behaviors in vascular formation and remodeling, Mediators 
Inflamm. 2013 (2013). doi:10.1155/2013/928315. 
[101] S.M. McCurdy, Q. Dai, J. Zhang, R. Zamilpa, T.A. Ramirez, T. Dayah, N. Nguyen, Y.-F. Jin, 
A.D. Bradshaw, M.L. Lindsey, SPARC mediates early extracellular matrix remodeling 
following myocardial infarction., Am. J. Physiol. Heart Circ. Physiol. 301 (2011) H497-505. 
doi:10.1152/ajpheart.01070.2010. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
25 
 
[102] E. Cavusoglu, J.D. Marmur, J.T. Kassotis, S. Yanamadala, V. Chopra, C. Eng, Usefulness 
of Plasma Matrix Metalloproteinase-3 Levels to Predict Myocardial Infarction in Men With 
and Without Acute Coronary Syndrome., Am. J. Cardiol. 117 (2016) 881–6. 
doi:10.1016/j.amjcard.2015.12.022. 
[103] M.L. Lindsey, G.P. Escobar, L.W. Dobrucki, D.K. Goshorn, S. Bouges, J.T. Mingoia, D.M. 
McClister, H. Su, J. Gannon, C. MacGillivray, R.T. Lee, A.J. Sinusas, F.G. Spinale, Matrix 
metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction., Am. 
J. Physiol. Heart Circ. Physiol. 290 (2006) H232-9. doi:10.1152/ajpheart.00457.2005. 
[104] A. Yabluchanskiy, Y. Li, L.E. de Castro Brás, K. Hakala, S.T. Weintraub, M.L. Lindsey, 
Proteomic analysis of the left ventricle post-myocardial infarction to identify in vivo candidate 
matrix metalloproteinase substrates., Methods Mol. Biol. 1066 (2013) 185–99. 
doi:10.1007/978-1-62703-604-7_16. 
[105] S.K. Miyasato, J. Loeffler, R. Shohet, J. Zhang, M. Lindsey, C.J. Le Saux, Caveolin-1 
modulates TGF-β1 signaling in cardiac remodeling., Matrix Biol. 30 (2011) 318–29. 
doi:10.1016/j.matbio.2011.05.003. 
[106] A. Erkol, S. Pala, V. Oduncu, A. Kılıcgedik, F. Kızılırmak, C. Karabay, A. Güler, C. Kırma, 
Relation of plasma matrix metalloproteinase-8 levels late after myocardial infarction with left 
ventricular volumes and ejection fraction, Turk Kardiyol. Dern. Arsivi-Archives Turkish Soc. 
Cardiol. 41 (2013) 617–624. doi:10.5543/tkda.2013.68625. 
[107] M.L. Lindsey, D.K. Goshorn, C.E. Squires, G.P. Escobar, J.W. Hendrick, J.T. Mingoia, S.E. 
Sweterlitsch, F.G. Spinale, Age-dependent changes in myocardial matrix 
metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function., 
Cardiovasc. Res. 66 (2005) 410–9. doi:10.1016/j.cardiores.2004.11.029. 
[108] A.M. Romanic, C.L. Burns-Kurtis, B. Gout, I. Berrebi-Bertrand, E.H. Ohlstein, Matrix 
metalloproteinase expression in cardiac myocytes following myocardial infarction in the 
rabbit., Life Sci. 68 (2001) 799–814. http://www.ncbi.nlm.nih.gov/pubmed/11205871. 
[109] S.C. Tyagi, S. Kumar, G. Glover, Induction of tissue inhibitor and matrix metalloproteinase 
by serum in human heart-derived fibroblast and endomyocardial endothelial cells., J. Cell. 
Biochem. 58 (1995) 360–71. doi:10.1002/jcb.240580309. 
[110] V. Arpino, M. Brock, S.E. Gill, The role of TIMPs in regulation of extracellular matrix 
proteolysis., Matrix Biol. 44–46 (2015) 247–54. doi:10.1016/j.matbio.2015.03.005. 
[111] L. Lu, J.Q. Zhang, F.J. Ramires, Y. Sun, Molecular and cellular events at the site of 
myocardial infarction: from the perspective of rebuilding myocardial tissue., Biochem. 
Biophys. Res. Commun. 320 (2004) 907–13. doi:10.1016/j.bbrc.2004.06.034. 
[112] V. Kandalam, R. Basu, T. Abraham, X. Wang, A. Awad, W. Wang, G.D. Lopaschuk, N. 
Maeda, G.Y. Oudit, Z. Kassiri, Early activation of matrix metalloproteinases underlies the 
exacerbated systolic and diastolic dysfunction in mice lacking TIMP3 following myocardial 
infarction., Am. J. Physiol. Heart Circ. Physiol. 299 (2010) H1012-23. 
doi:10.1152/ajpheart.00246.2010. 
[113] E. Cavusoglu, C. Ruwende, V. Chopra, S. Yanamadala, C. Eng, L.T. Clark, D.J. Pinsky, J.D. 
Marmur, Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-
cause mortality, cardiac mortality, and myocardial infarction., Am. Heart J. 151 (2006) 
1101.e1-8. doi:10.1016/j.ahj.2006.02.029. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
26 
 
[114] S.H. Ahmed, L.L. Clark, W.R. Pennington, C.S. Webb, D.D. Bonnema, A.H. Leonardi, C.D. 
McClure, F.G. Spinale, M.R. Zile, Matrix metalloproteinases/tissue inhibitors of 
metalloproteinases: relationship between changes in proteolytic determinants of matrix 
composition and structural, functional, and clinical manifestations of hypertensive heart 
disease., Circulation. 113 (2006) 2089–96. doi:10.1161/CIRCULATIONAHA.105.573865. 
[115] E.E.J.M. Creemers, J.N. Davis, A.M. Parkhurst, P. Leenders, K.B. Dowdy, E. Hapke, A.M. 
Hauet, P.G. Escobar, J.P.M. Cleutjens, J.F.M. Smits, M.J.A.P. Daemen, M.R. Zile, F.G. 
Spinale, Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in 
mice., Am. J. Physiol. Heart Circ. Physiol. 284 (2003) H364-71. 
doi:10.1152/ajpheart.00511.2002. 
[116] S.R. Eckhouse, B.P. Purcell, J.R. McGarvey, D. Lobb, C.B. Logdon, H. Doviak, J.W. O’Neill, 
J.A. Shuman, C.P. Novack, K.N. Zellars, S. Pettaway, R.A. Black, A. Khakoo, T. Lee, R. 
Mukherjee, J.H. Gorman, R.C. Gorman, J.A. Burdick, F.G. Spinale, Local hydrogel release 
of recombinant TIMP-3 attenuates adverse left ventricular remodeling after experimental 
myocardial infarction., Sci. Transl. Med. 6 (2014) 223ra21. 
doi:10.1126/scitranslmed.3007244. 
[117] J.R. Meds, A. Zhang, T.F. Meds, Biomarkers of myocardial infarction : past , present and 
future, (2015) 23–25. 
[118] M.I. Ahmad, N. Sharma, Biomarkers in Acute Myocardial Infarction, 3 (2012). 
doi:10.4172/2155-9880.1000222. 
[119] W. Gerhardt, H. Katus, J. Ravkilde, P. L, C. Hnmm, P.J. J, E. Peheim, L. Ljungdahl, S-
Troponin T in Suspected lschemic Myocardial Injury Compared with Mass and Catalytic 
Concentrations of S-Creatine Kinase lsoenzyme MB, 37 (1991) 1405–1411. 
[120] J.L. Sepulveda, J.L. Mehta, C-reactive protein and cardiovascular disease: a critical 
appraisal., Curr. Opin. Cardiol. 20 (2005) 407–16. 
doi:10.1097/01.hco.0000175518.57804.94. 
[121] M. Dietrich, I. Jialal, The effect of weight loss on a stable biomarker of inflammation, C-
reactive protein., Nutr. Rev. 63 (2005) 22–8. http://www.ncbi.nlm.nih.gov/pubmed/15730232. 
[122] G.P. Young, W.B. Gibler, J.R. Hedges, J.W. Hoekstra, C. Slovis, R. Aghababian, M. Smith, 
M. Rubison, J. Ellis, Serial creatine kinase-MB results are a sensitive indicator of acute 
myocardial infarction in chest pain patients with nondiagnostic electrocardiograms: the 
second Emergency Medicine Cardiac Research Group Study., Acad. Emerg. Med. 4 (1997) 
869–77. http://www.ncbi.nlm.nih.gov/pubmed/9305428. 
[123] B. Jurlander, P. Clemmensen, G.S. Wagner, P. Grande, Very early diagnosis and risk 
stratification of patients admitted with suspected acute myocardial infarction by the 
combined evaluation of a single serum value of cardiac troponin-T, myoglobin, and creatine 
kinase MB(mass), Eur. Heart J. 21 (2000) 382–389. doi:10.1053/euhj.1999.1760. 
[124] L.K. Newby, A.B. Storrow, W.B. Gibler, J.L. Garvey, J.F. Tucker, A.L. Kaplan, D.H. 
Schreiber, R.H. Tuttle, S.E. Mcnulty, E.M. Ohman, Clinical Investigation and Reports 
Bedside Multimarker Testing for Risk Stratification in, Circulation. (2001) 1832–1837. 
[125] S.M. Sallach, R. Nowak, M.P. Hudson, G. Tokarski, N. Khoury, M.C. Tomlanovich, G. 
Jacobsen, J.A. de Lemos, J. McCord, A change in serum myoglobin to detect acute 
myocardial infarction in patients with normal troponin I levels, Am. J. Cardiol. 94 (2004) 864–
867. doi:10.1016/j.amjcard.2004.06.019. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
27 
 
[126] E. Vassiliadis, N. Barascuk, A. Didangelos, M. a Karsdal, Novel cardiac-specific biomarkers 
and the cardiovascular continuum., Biomark. Insights. 7 (2012) 45–57. 
doi:10.4137/BMI.S9536. 
[127] F.G. Warburton, A. Bernstein, A.N.N.C. Wright, SERUM CREATINE PHOSPHOKINASE 
ESTIMATIONS IN, (1965). 
[128] M. a Karsdal, M.J. Nielsen, J.M. Sand, K. Henriksen, F. Genovese, A.-C. Bay-Jensen, V. 
Smith, J.I. Adamkewicz, C. Christiansen, D.J. Leeming, Extracellular matrix remodeling: the 
common denominator in connective tissue diseases. Possibilities for evaluation and current 
understanding of the matrix as more than a passive architecture, but a key player in tissue 
failure., Assay Drug Dev. Technol. 11 (2013) 70–92. doi:10.1089/adt.2012.474. 
[129] R.G. Jenkins, J.K. Simpson, G. Saini, J.H. Bentley, A.-M. Russell, R. Braybrooke, P.L. 
Molyneaux, T.M. McKeever, A.U. Wells, A. Flynn, R.B. Hubbard, D.J. Leeming, R.P. 
Marshall, M.A. Karsdal, P.T. Lukey, T.M. Maher, Longitudinal change in collagen 
degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, 
multicentre PROFILE study, Lancet Respir. Med. 3 (2015) 462–472. doi:10.1016/S2213-
2600(15)00048-X. 
[130] J.M.B. Sand, D.J. Leeming, I. Byrjalsen, A.R. Bihlet, P. Lange, R. Tal-Singer, B.E. Miller, 
M.A. Karsdal, J. Vestbo, High levels of biomarkers of collagen remodeling are associated 
with increased mortality in COPD ? results from the ECLIPSE study, Respir. Res. 17 (2016) 
125. doi:10.1186/s12931-016-0440-6. 
[131] D. Stolz, D.J. Leeming, J.H.E. Kristensen, M.A. Karsdal, W. Boersma, R. Louis, B. 
Milenkovic, K. Kostikas, F. Blasi, J. Aerts, J.M.B. Sand, E.F.M. Wouters, G. Rohde, C. Prat, 
A. Torres, T. Welte, M. Roth, E. Papakonstantinou, M. Tamm, Systemic Biomarkers of 
Collagen and Elastin Turnover Are Associated With Clinically Relevant Outcomes in COPD, 
Chest. 151 (2017) 47–59. doi:10.1016/j.chest.2016.08.1440. 
[132] J.M.B. Sand, G. Martinez, A.-K. Midjord, M.A. Karsdal, D.J. Leeming, P. Lange, 
Characterization of serological neo-epitope biomarkers reflecting collagen remodeling in 
clinically stable chronic obstructive pulmonary disease, Clin. Biochem. 49 (2016) 1144–
1151. doi:10.1016/j.clinbiochem.2016.09.003. 
[133] A.R. Bihlet, M.A. Karsdal, J.M.B. Sand, D.J. Leeming, M. Roberts, W. White, R. Bowler, 
Biomarkers of extracellular matrix turnover are associated with emphysema and 
eosinophilic-bronchitis in COPD, Respir. Res. 18 (2017) 22. doi:10.1186/s12931-017-0509-
x. 
[134] E.G.D. Stribos, S.H. Nielsen, S. Brix, M.A. Karsdal, M.A. Seelen, H. van Goor, S.J.L. 
Bakker, P. Olinga, H.A.M. Mutsaers, F. Genovese, Non-invasive quantification of collagen 
turnover in renal transplant recipients, PLoS One. 12 (2017) e0175898. 
doi:10.1371/journal.pone.0175898. 
[135] A. Fenton, M.D. Jesky, C.J. Ferro, J. S?rensen, M.A. Karsdal, P. Cockwell, F. Genovese, 
Serum endotrophin, a type VI collagen cleavage product, is associated with increased 
mortality in chronic kidney disease, PLoS One. 12 (2017) e0175200. 
doi:10.1371/journal.pone.0175200. 
[136] F. Genovese, P. Boor, M. Papasotiriou, D.J. Leeming, M.A. Karsdal, J. Floege, Turnover of 
type III collagen reflects disease severity and is associated with progression and 
microinflammation in patients with IgA nephropathy, Nephrol. Dial. Transplant. 31 (2016) 
472–479. doi:10.1093/ndt/gfv301. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
28 
 
[137] R. Eschalier, M. Fertin, R. Fay, C. Bauters, F. Zannad, F. Pinet, P. Rossignol, Extracellular 
matrix turnover biomarkers predict long-term left ventricular remodeling after myocardial 
infarction: insights from the REVE-2 study., Circ. Heart Fail. 6 (2013) 1199–205. 
doi:10.1161/CIRCHEARTFAILURE.113.000403. 
[138] O. Barthélémy, F. Beygui, E. Vicaut, S. Rouanet, E. Van Belle, C. Baulac, A. Degrandsart, J. 
Dallongeville, G. Montalescot, OPERA Investigators, Relation of high concentrations of 
plasma carboxy-terminal telopeptide of collagen type I with outcome in acute myocardial 
infarction., Am. J. Cardiol. 104 (2009) 904–9. doi:10.1016/j.amjcard.2009.05.029. 
[139] E. Barasch, J.S. Gottdiener, G. Aurigemma, D.W. Kitzman, J. Han, W.J. Kop, R.P. Tracy, 
Association between elevated fibrosis markers and heart failure in the elderly: the 
cardiovascular health study., Circ. Heart Fail. 2 (2009) 303–10. 
doi:10.1161/CIRCHEARTFAILURE.108.828343. 
[140] R. Lombardi, S. Betocchi, M.A. Losi, C.G. Tocchetti, M. Aversa, M. Miranda, G. 
D’Alessandro, A. Cacace, Q. Ciampi, M. Chiariello, Myocardial collagen turnover in 
hypertrophic cardiomyopathy., Circulation. 108 (2003) 1455–60. 
doi:10.1161/01.CIR.0000090687.97972.10. 
[141] R. Martos, J. Baugh, M. Ledwidge, C. O’Loughlin, C. Conlon, A. Patle, S.C. Donnelly, K. 
McDonald, Diastolic heart failure: evidence of increased myocardial collagen turnover linked 
to diastolic dysfunction., Circulation. 115 (2007) 888–95. 
doi:10.1161/CIRCULATIONAHA.106.638569. 
[142] R. Plaksej, W. Kosmala, S. Frantz, S. Herrmann, M. Niemann, S. Störk, R. Wachter, C.E. 
Angermann, G. Ertl, B. Bijnens, F. Weidemann, Relation of circulating markers of fibrosis 
and progression of left and right ventricular dysfunction in hypertensive patients with heart 
failure., J. Hypertens. 27 (2009) 2483–91. doi:10.1097/HJH.0b013e3283316c4d. 
[143] F.A. Kamal, K. Watanabe, M. Ma, Y. Abe, R. Elbarbary, M. Kodama, Y. Aizawa, A novel 
phenylpyridazinone, T-3999, reduces the progression of autoimmune myocarditis to dilated 
cardiomyopathy., Heart Vessels. 26 (2011) 81–90. doi:10.1007/s00380-010-0018-z. 
[144] Y.-H. Liu, M. D’Ambrosio, T. Liao, H. Peng, N.-E. Rhaleb, U. Sharma, S. André, H.-J. 
Gabius, O.A. Carretero, N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling 
and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin., 
Am. J. Physiol. Heart Circ. Physiol. 296 (2009) H404-12. doi:10.1152/ajpheart.00747.2008. 
[145] S. Psarras, M. Mavroidis, D. Sanoudou, C.H. Davos, G. Xanthou, A.E. Varela, V. 
Panoutsakopoulou, Y. Capetanaki, Regulation of adverse remodelling by osteopontin in a 
genetic heart failure model., Eur. Heart J. 33 (2012) 1954–63. doi:10.1093/eurheartj/ehr119. 
[146] R.A.P. Weir, C.J. Petrie, C.A. Murphy, S. Clements, T. Steedman, A.M. Miller, I.B. McInnes, 
I.B. Squire, L.L. Ng, H.J. Dargie, J.J. V McMurray, Galectin-3 and cardiac function in 
survivors of acute myocardial infarction., Circ. Heart Fail. 6 (2013) 492–8. 
doi:10.1161/CIRCHEARTFAILURE.112.000146. 
[147] A.R. van der Velde, W.C. Meijers, J.E. Ho, F.P. Brouwers, M. Rienstra, S.J.L. Bakker, A.C. 
Muller Kobold, D.J. van Veldhuisen, W.H. van Gilst, P. van der Harst, R.A. de Boer, Serial 
galectin-3 and future cardiovascular disease in the general population., Heart. 102 (2016) 
1134–41. doi:10.1136/heartjnl-2015-308975. 
[148] G. V Halade, Y.-F. Jin, M.L. Lindsey, Matrix metalloproteinase (MMP)-9: a proximal 
biomarker for cardiac remodeling and a distal biomarker for inflammation., Pharmacol. Ther. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
29 
 
139 (2013) 32–40. doi:10.1016/j.pharmthera.2013.03.009. 
[149] M.L. Lindsey, M.E. Hall, R. Harmancey, Y. Ma, Adapting extracellular matrix proteomics for 
clinical studies on cardiac remodeling post-myocardial infarction., Clin. Proteomics. 13 
(2016) 19. doi:10.1186/s12014-016-9120-2. 
[150] K.P. Quinn, K.E. Sullivan, Z. Liu, Z. Ballard, C. Siokatas, I. Georgakoudi, L.D. Black, Optical 
metrics of the extracellular matrix predict compositional and mechanical changes after 
myocardial infarction., Sci. Rep. 6 (2016) 35823. doi:10.1038/srep35823. 
[151] M.L. Lindsey, R.P. Iyer, R. Zamilpa, A. Yabluchanskiy, K.Y. DeLeon-Pennell, M.E. Hall, A. 
Kaplan, F.A. Zouein, D. Bratton, E.R. Flynn, P.L. Cannon, Y. Tian, Y.-F. Jin, R.A. Lange, D. 
Tokmina-Roszyk, G.B. Fields, L.E. de Castro Brás, A Novel Collagen Matricryptin Reduces 
Left Ventricular Dilation Post-Myocardial Infarction by Promoting Scar Formation and 
Angiogenesis., J. Am. Coll. Cardiol. 66 (2015) 1364–74. doi:10.1016/j.jacc.2015.07.035. 
[152] R.P. Iyer, M. Jung, M.L. Lindsey, MMP-9 signaling in the left ventricle following myocardial 
infarction., Am. J. Physiol. Heart Circ. Physiol. 311 (2016) H190-8. 
doi:10.1152/ajpheart.00243.2016. 
[153] M.L. Lindsey, R.P. Iyer, M. Jung, K.Y. DeLeon-Pennell, Y. Ma, Matrix metalloproteinases as 
input and output signals for post-myocardial infarction remodeling., J. Mol. Cell. Cardiol. 91 
(2016) 134–40. doi:10.1016/j.yjmcc.2015.12.018. 
[154] M.L. Lindsey, M. Mayr, A. V Gomes, C. Delles, D.K. Arrell, A.M. Murphy, R.A. Lange, C.E. 
Costello, Y.-F. Jin, D.T. Laskowitz, F. Sam, A. Terzic, J. Van Eyk, P.R. Srinivas, American 
Heart Association Council on Functional Genomics and Translational Biology, Council on 
Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on 
Cardiovascular and Stroke Nursing, Council on Hypertension, and Stroke Council, 
Transformative Impact of Proteomics on Cardiovascular Health and Disease: A Scientific 
Statement From the American Heart Association., Circulation. 132 (2015) 852–72. 
doi:10.1161/CIR.0000000000000226. 
[155] S. Amar, D. Minond, G.B. Fields, Clinical Implications of Compounds Designed to Inhibit 
ECM-Modifying Metalloproteinases., Proteomics. (2017) 1600389. 
doi:10.1002/pmic.201600389. 
[156] C.A. Meschiari, O.K. Ero, H. Pan, T. Finkel, M.L. Lindsey, The impact of aging on cardiac 
extracellular matrix., GeroScience. 39 (2017) 7–18. doi:10.1007/s11357-017-9959-9. 
[157] A. Manninen, M. Varjosalo, A proteomics view on integrin-mediated adhesions., Proteomics. 
17 (2017) 1600022. doi:10.1002/pmic.201600022. 
[158] D.J. Luther, C.K. Thodeti, P.E. Shamhart, R.K. Adapala, C. Hodnichak, D. Weihrauch, P. 
Bonaldo, W.M. Chilian, J.G. Meszaros, Absence of type VI collagen paradoxically improves 
cardiac function, structure, and remodeling after myocardial infarction., Circ. Res. 110 
(2012) 851–6. doi:10.1161/CIRCRESAHA.111.252734. 
[159] N.A. Trueblood, Z. Xie, C. Communal, F. Sam, S. Ngoy, L. Liaw, A.W. Jenkins, J. Wang, 
D.B. Sawyer, O.H. Bing, C.S. Apstein, W.S. Colucci, K. Singh, Exaggerated left ventricular 
dilation and reduced collagen deposition after myocardial infarction in mice lacking 
osteopontin., Circ. Res. 88 (2001) 1080–7. http://www.ncbi.nlm.nih.gov/pubmed/11375279. 
[160] K. Singh, G. Sirokman, C. Communal, K.G. Robinson, C.H. Conrad, W.W. Brooks, O.H. 
Bing, W.S. Colucci, Myocardial osteopontin expression coincides with the development of 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
30 
 
heart failure., Hypertens. (Dallas, Tex.  1979). 33 (1999) 663–70. 
http://www.ncbi.nlm.nih.gov/pubmed/10024324. 
[161] P. Snider, K.N. Standley, J. Wang, M. Azhar, T. Doetschman, S.J. Conway, Origin of 
cardiac fibroblasts and the role of periostin., Circ. Res. 105 (2009) 934–47. 
doi:10.1161/CIRCRESAHA.109.201400. 
[162] D. Kelly, S. Khan, G. Cockerill, L.L. Ng, M. Thompson, N.J. Samani, I.B. Squire, Circulating 
Stromelysin-1 (MMP-3): A novel predictor of LV dysfunction, remodelling and all-cause 
mortality after acute myocardial infarction, Eur. J. Heart Fail. 10 (2008) 133–139. 
doi:10.1016/j.ejheart.2007.12.009. 
[163] S.W.M. van den Borne, J.P.M. Cleutjens, R. Hanemaaijer, E.E. Creemers, J.F.M. Smits, 
M.J.A.P. Daemen, W.M. Blankesteijn, Increased matrix metalloproteinase-8 and -9 activity 
in patients with infarct rupture after myocardial infarction., Cardiovasc. Pathol. 18 (2009) 37–
43. doi:10.1016/j.carpath.2007.12.012. 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
31 
 
Figure legends 
 
Figure 1. Cellular and molecular events during the three phases 1) Inflammation, 2) 
Wound Healing and 3) Collagen deposition post-MI. 
 
Figure 2. Illustration of the changes occurring in the ECM remodeling during development 
of MI. 
 
Figure 3. Neo-epitope markers detecting ECM remodeling. A) Formation of detectable 
neo-epitopes generated by cleavage of ECM proteins by specific proteases. B) In the 
absence of proteolytic cleavage, the ECM protein is not recognized by the antibody.  
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
32 
 
Tables 
 
Table 1. Major myocardial extracellular matrix proteins and their functions 
Protein Function Localization Change 
during MI 
Reference 
Collagen I   Tensile strength and 
structural support 
Interstitial matrix ↑ [30,31] 
Collagen III  Tissue elasticity  Interstitial matrix ↑ [30,31,34] 
Collagen IV Maintain basement 
membrane 
architecture 
Basement 
membrane 
↑ [49] 
Collagen VI Organization of 
fibrillar 
collagens/Anchoring 
to basement 
membrane 
Interstitial 
matrix/basement 
membrane 
↑ [158] 
Elastin Tissue elasticity and 
recoil capability  
Interstitial matrix ↑ [52] 
Fibronectin Infiltration of 
connective tissue 
and inflammatory 
cells 
Interstitial matrix ↑ [56] 
Galectin-3 Apposition of ECM 
proteins and 
increased collagen 
turnover. 
Interstitial matrix ↑ [65] 
Laminin Maintain basement 
membrane 
architecture, cell 
migration, and 
angiogenesis 
Basement 
membrane 
↑ [46] 
Osteopontin Mediate adhesion, 
migration, growth, 
and differentiation 
Interstitial matrix ↑ [159,160] 
Periostin Collagen 
fibrillogenesis and 
overall organization 
of ECM 
Interstitial matrix ↑ [161] 
Decorin Bind to collagen 
type I and III, and 
affect formation of 
collagen fibrils 
Interstitial matrix ↑ [63] 
Versican Mediate 
inflammatory cell-
cell and cell-matrix 
interactions 
Interstitial matrix ↑ [67] 
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Table 2. MMPs and TIMPs involved in MI remodeling 
MMP/TIMP Expression 
post-MI 
Biological roles Reference 
MMP-1 ↑ Degrade collagen type I and III 
MMP-1:TIMP-1 ratio is 
correlated with ejection fraction 
[86] 
MMP-2 ↑ Increased LV rupture and delay 
post-MI remodeling 
[91–93] 
MMP-3 ↑ Increased risk of long-term MI 
and independent predictor of LV 
systolic dysfunction 
[162] 
MMP-7 ↑ Deletion attenuates LV dilation 
post-MI 
[21] 
MMP-8 ↑ Early increase of MMP-8 is 
correlated with poor prognosis 
and promote infarct rupture in 
humans by degradation of 
collagens 
[163] 
MMP-9 ↑ MMP-9 deletion attenuated LV 
dilation post-MI 
[95,96] 
MMP-12 ↑ MMP-12 inhibition exacerbates 
cardiac dysfunction 
[61] 
MMP-28 ↑ MMP-28 deletion aggravated 
MI-induced LV dysfunction 
Increased LV rupture 
 
[5] 
TIMP-1 ↑ Associate with markers of HF 
severity, systemic inflammation 
and LV remodeling 
MMP-1:TIMP-1 ratio is 
correlated with ejection fraction 
[107,109] 
TIMP-2 ↑ Correlate with ECM deposition [91] 
TIMP-3 ↓ Cardioprotective and reduced 
post-MI 
[114,116] 
TIMP-4 ↓ Deletion attenuates increased 
LV rupture and mortality 
[114] 
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Highlights 
• This review focuses on post-MI LV ECM remodeling, targeting the discussion on ECM 
biomarkers that could be useful for predicting MI outcomes.  
